Definium Therapeutics (DFTX) Treasury Shares (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Treasury Shares data on file, last reported at $8.2 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $8.2 million, up 37.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 million (up 37.43% YoY), and the FY2025 annual result was $5.5 million, up 297.97% from the prior year.
• Treasury Shares climbed to $8.2 million in Q1 2026 per DFTX's latest filing, from $5.5 million in the prior quarter.
• Over five years, Treasury Shares peaked at $14.0 million in Q1 2022 and troughed at $792860.0 in Q1 2024.
• A 5-year average of $3.8 million and a median of $2.3 million in 2023 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2023 and 2025: Treasury Shares plunged 89.98% in 2023, then soared 650.3% in 2025.
• A 5-year view of Treasury Shares shows it stood at $1.5 million in 2022, then jumped by 50.3% to $2.3 million in 2023, then tumbled by 40.09% to $1.4 million in 2024, then jumped by 297.97% to $5.5 million in 2025, then surged by 49.81% to $8.2 million in 2026.
• Business Quant data shows DFTX's Treasury Shares at $8.2 million in Q1 2026, $5.5 million in Q4 2025, and $5.8 million in Q3 2025.